Robert James Staab, Ph.D., D.A.B.T., R.A.C.
Dr. Staab started his professional career by developing a safety program for American Cyanamid Products (Breck, Old Spice, Pine Sol, and et.al.) During this time he worked closely with many trade organizations including the Cosmetic, Toiletry, and Fragrance Association.
He next served Exxon Corporation in both the US and Europe dealing with the regulatory and safety issues of direct food additives and skin contact petroleum and chemical products. During this period he developing an appreciation for international markets and their regulatioy issues.
As Director of Product Safety and Regulatory Affairs for Tambrands, Dr. Staab developed a safety program for the women’s health care product, Tampax Tampons, and many other women’s health care products that were under development. This program was reviewed and commented upon extensively by the FDA. During this period Dr. Staab worked closely with the FDA and regulatory bodies in Japan, the former USSR, Mexico, the United Kingdom, Italy, Sweden and others.
After joining London International as Vice President of Scientific Affairs during the height of the AIDS epidemic, Dr. staab addressed a number of important issues for the condom and spermicide industry. The products include those currently on the market as well as several that were in the experimental stage.
Dr. Staab has several patents in the field of drug delivery. He is board certified in toxicology (DABT), regulatory affairs, (RAC) safety (CSE WSO) and is a chartered biologist by the Institute of Biology, London (CBiol MIBiol). As a consultant to many pharmaceutical, medical device, cosmetic, food, and chemical companies, Dr. Staab provides consulting services directed towards ensuring safe and efficacious products as they reach the market following expeditious review by the FDA or other regulatory bodies. He has chaired three investigational review boards with his tenure at the Allendale investigational review Board (AIRB) since 1990 as chairman.
Ira W. Daly, Ph.D., D.A.B.T., R.A.C.
Dr. Daly has over 30 years of experience in preclinical drug development, toxicology and regulatory affairs. He is board certified in toxicology, (DABT, by the American Board of Toxicology), and regulatory affairs, (RAC, by the Regulatory Affairs Professional Society) and he is a chartered biologist by the Institute of Biology, London (CBiol MIBiol).
Dr. Daly began his professional career with Warner Lambert where he was involved in product development and safety for over-the-counter gastrointestinal and respiratory drugs and consumer products.
Dr Daly joined Bio/dynamics, Inc., a major contract research organization, in 1978 and over the next 19 years served in a number of scientific and management positions. During this time he served as a study directory and program manager for over one thousand toxicology investigations conducted in animal species ranging from rodents to primates that were used to support international drug, medical device, food additive and chemical registrations. In his capacity as Senior Vice President and Director of Toxicology Dr. Daly was responsible for laboratory and scientific operations in the areas of rodent, canine and primate toxicology, reproduction, inhalation and cardiovascular toxicology, intravenous infusion technology and metabolism and analytical chemistry.
Dr. Daly joined Regulatory and Technical Associates, Inc in 1997 as Executive Vice President. In this capacity he serves as a consultant in toxicology, preclinical drug development and regulatory affairs for an international client base. He is directly involved in preclinical program design and management as well as in the preparation of regulatory submissions.
Philip Eskola, Ph.D.
Dr. Eskola has over 30 years of experience in pharmaceutical chemistry with extensive experience in organic and analytical chemistry with Merck. Dr. Eskola assists RTA clients with pharmaceutical chemistry problems assuring submissions and projects flow smoothly.
During his time at Merck Dr. Eskola developed biologically active compounds for both the human and animal health markets. This resulted in the synthesis of many preclinical candidates and approval of several anthelmintic agents for both human and animal use. Most important of these was Ivermectin, a broad spectrum anti-parasitic agent which has been formulated as "Heartgard" for dogs and cats. However, the most profound formulation of Ivermectin was as "Mectizan." This drug has been donated by Merck to the World Health Organization since 1988 for treatment of over 600 million people suffering from the parasitic disease "River Blindness" in Africa and South America. Later in his career at Merck, Dr. Eskola led the Synthetic Services Group. This group was responsible for supporting the chemical and instrumental needs of 430 chemists in the Medicinal Chemistry department of MRL in Rahway, NJ. The group synthesized and\or purified intermediates and final biologically active compounds for further development or biological testing. Dr. Eskola is familiar with organic synthesis, normal and reversed-phase chromatograpghy, all instrumental techniques for identifying organic molecules, and methods for determining their purity.